Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT02780778
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Targeted therapy Apatinib：500 mg，po，qd
  • Docetaxel — DRUG
    chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w

Study Details

The purpose of this Phase II, Open-label, single arm, exploratory study is to evaluate the efficacy and the safety of Apatinib（500mg/d）with docetaxel (60 mg/m²) in advanced Non-squamous Non-small cell lung cancer after failure of first line chemotherapy.

Key Dates

Start date
May 31, 2016
Status verified
Apr 2016
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING

Arms

  • Experimental: Treatment group
    Apatinib：500 mg，po，qd； Docetaxel：60mg/m²，vein input 1hour，every 3w

Primary Outcome Measure

progression-free survival [ Time Frame: 1 Day ]

Central Contacts

Related Studies